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Abstract 23 
CD44 is a multifunctional cell surface protein involved in proliferation and 24 
differentiation, angiogenesis and signaling. The expression of CD44 is up-regulated in 25 
several types of human tumors and particularly in cancer stem cells, representing an 26 
appealing target for drug delivery in the treatment of cancer. We have explored here 27 
several protein ligands of CD44 for the construction of self-assembling modular 28 
proteins designed to bind and internalize target cells. Among five tested ligands, two of 29 
them (A5G27 and FNI/II/V) drive the formation of protein-only, ring-shaped 30 
nanoparticles of about 14 nm that efficiently bind and penetrate CD44+ cells by an 31 
endosomal route. The potential of these newly designed nanoparticles is evaluated 32 
regarding the need of biocompatible nanostructured materials for drug delivery in 33 
CD44-linked conditions. 34 
 35 
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1. Introduction 39 
CD44 is a transmembrane adhesion glycoprotein which participates in cell-cell and cell-40 
extracellular matrix interactions, being hyaluronic acid (HA), fibronectin and laminin its 41 
natural ligands. CD44 is expressed in many cell lines including leukocytes and 42 
fibroblasts and it participates in a wide range of physiological processes such as cell 43 
migration, lymphocyte homing, cell activation and hematopoiesis (Gee et al. 2004). 44 
Among several surface receptors overexpressed in cancer stem cells (CSCs), including 45 
CD133, CD44, CD49 and ITGA6, CD44 is the most frequent molecular marker, being 46 
present in a large variety of tumor types. It is prevalent in highly recurrent colon, liver, 47 
prostate or breast cancers (Zoller, 2011).The tumorigenic and metastatic potential of 48 
CSCs have been associated to CD44 expression. Many evidences strongly support 49 
that an alteration of CD44 expression levels promotes tumor cell survival and 50 
aggressiveness and it also induces tumorogenesis and metastasis. In this regard, cell 51 
lines which highly express CD44 are capable of forming more aggressive tumors in the 52 
invading tissue (Goodison, Urquidi et al., 1999). In breast cancer, CD44 is not only a 53 
useful stem cell marker but also a promising therapeutic target (Marangoni, Lecomte et 54 
al., 2009; Sauter, Kloft et al., 2007; Tijink, Buter et al., 2006), and targeting to CD44 55 
reduces tumor growth and prevents post-chemotherapy relapse of human breast 56 
cancer xenografts (Marangoni, Lecomte et al., 2009). In humans, anti-CD44 antibodies 57 
used as targeting agents for either radiolabels or anticancer chemotherapeutics have 58 
shown promise in clinical trials, and disease stabilization was observed in patients with 59 
breast or head and neck tumors treated with anti-CD44-based conjugates (Sauter, Kloft 60 
et al., 2007; Tijink, Buter et al., 2006).   61 
In the drug delivery scenario, a diversity of materials including natural polymers, carbon 62 
nanotubes and lipid-based and inorganic nanoparticles have been proposed for the 63 
specific targeting CD44-expressing cells, upon convenient functionalization. Most of 64 
them have been formulated by the conjugation of a given nano-vehicle with HA acid 65 
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(Peer, Karp et al., 2007), but in general, preliminary results have been not dramatically 66 
promising. Apart from toxicity issues (Goodison, Urquidi et al., 1999), not all CD44 + 67 
cells constitutively bind HA, as the binding capacity appears to be influenced by 68 
structural variation and/or CD44 glycosilation patterns (Gee, Kryworuchko et al., 2004; 69 
Zoller, 2011). In this regard, CD44-binding proteins are promising alternatives to HA as 70 
targeting agents, and the use of these proteins as functionalizing agents would offer 71 
the flexibility of protein engineering in nanoparticle design. However, while CD44 has 72 
been described to undergo receptor-mediated endocytosis when bound to HA and 73 
collagen (Koo, Huh et al., 2011; Rezler, Khan et al., 2007), evidences supporting 74 
internalisation of laminin and fibronectin are still missing. 75 
In the present study and by applying a nano-architectonic principle based on the 76 
combined use of end terminal cationic peptides and polyhistidines (Ferrer-Miralles, 77 
Corchero et al., 2011; Unzueta, Cespedes et al., 2012; Unzueta, Ferrer-Miralles et al., 78 
2012), we have explored five CD44-specific protein ligands as components of 79 
multifunctional chimerical proteins, with potential for oligomerization. Among them, two 80 
peptides from laminin and fibronectin, respectively, efficiently target CD44+ cells and in 81 
addition, they promote the self-assembling of the carrier protein as functional 82 
nanoparticles of 14 nm. Such particulate organization confers added value properties 83 
to protein constructs, favouring cellular penetrability and opening a plethora of 84 
possibilities for the rational design of protein-based, fully biocompatible nano-85 
medicines, that in form of viral biomimetics, target CD44-overexpressing cells. 86 
 87 
88 
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2. Materials and methods 89 
2.1. Cell lines and media. MDA-MB-231 cell line was maintained in RPMI 1640 90 
supplemented with 10 % foetal calf serum (FBS) and 6 mM GlutaMAX (Invitrogen), and 91 
MCF-7 in Dulbecco's Modified Eagle Medium (DMEM) F12 supplemented with 10 % 92 
foetal bovine serum (FBS) and 2 mM GlutaMAX (Invitrogen). HepG2 (ATCC HB-8065) 93 
cell line was maintained in MEM-α (Invitrogen) supplemented with 10 % FBS and 2 94 
mMGlutaMAX. All cell types were incubated at 37°C and 5 % CO2  except HEK-293-T, 95 
which was maintained at 10% CO2 in DMEM supplemented with 10% FBS and 2 96 
mMGlutaMAX.  97 
2.2. Protein design, production, purification, and characterization. Five chimeric 98 
genes were designed in-house and provided by GenScript (Hong Kong, China). The 99 
resulting fusion proteins (Figure 1 A) were named according to their modular 100 
organization as Nterm-Peptide-GFP- H6-Cterm, being all N terminal peptides known CD44 101 
ligands (Table 1). Using NdeI/HindIII restriction sites, segments of these genes were 102 
inserted into pET22b expression plasmid (Novagen 69744-3). Fibroblast growth factor 103 
2 (FGF2-H6), as CD44 overexpression activator, was produced as described for the 104 
proteins above. All the encoded proteins were produced in Escherichia coli BL21 (F–105 
ompThsdSB(rB
– mB
–) gal dcmDE3, Novagen) overnight at 16°C for A5G27-GFP-106 
H6,FNI/II/V-GFP-H6 and FGF2-H6, overnight at 20ºC for FNI-GFP-H6 and P7-GFP-H6 107 
and during 3 h at 37ºC for FNV-GFP-H6. Gene expression was induced upon the 108 
addition of 1 mM IPTG. Bacterial cells were then centrifuged for 45 min (5000 g at 4°C) 109 
and resuspended in Tris buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole) 110 
in the presence of protease inhibitor (Complete EDTA-Free, Roche, Basel, 111 
Switzerland). The cells were disrupted at 1200 psi in a French press (Thermo 112 
Scioentific). Lysates were centrifuged at 15,000g for 45 min and soluble fractions were 113 
filtrated before His-tag affinity chromatography using HiTrap Chelating HP 1 mL 114 
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columns (GE Healthcare, Piscataway, NJ) with an AKTA purifier FPLC (GE 115 
Healthcare). Elution was achieved by a linear gradient of 20 mM Tris, pH 8.0, 500 mM 116 
NaCl, and 500 mM imidazole, and the eluted material was analyzed by Western 117 
Blotting with an anti-His monoclonal antibody (Santa Cruz Biotechnology Inc., 118 
Heidelberg, Germany) to observe the presence of the protein of interest. An anion-119 
exchange chromatography was additionally performed for A5G27-GFP-H6 and 120 
FNI/II/V-GFP-H6 proteins purification using DEAE HP and QFF HP 1 ml columns (GE 121 
Healthcare) respectively and a linear gradient of 10 mM Tris-HCl pH 8.0, 1 M NaCl for 122 
A5G27-GFP-H6 and 166 mMNaHCO3, 1 M NaCl for FNI/II/V-GFP-H6. Proteins were 123 
finally dialyzed overnight at 4ºC against sodium bicarbonate buffer (166 mM NaHCO3 at 124 
pH 7.4) except for FGF2-H6 that was dialysed with phosphate buffer (0.1 M NaPO3, pH 125 
6.3). Protein integrity and purity were checked by Coomassie Brilliant Blue staining, by 126 
mass spectrometry (MALDI-TOF) and N-terminal sequencing using the Edman 127 
degradation method. Protein concentration was determined by Bradford assay as 128 
described elsewhere (Bradford, 1976). A5G27-GFP-H6, FNV-GFP-H6 and FNI/II/V-129 
GFP-H6 had been preliminarily screened for self-assembling in a previous study 130 
(Unzueta, Ferrer-Miralles et al., 2012). Protein production was supported by Protein 131 
Production Platform (CIBER-BBN – UAB, http://www.ciber-bbn.es/en/programas/89-132 
plataforma-de-produccion-de-proteinas-ppp). 133 
2.3. Atomic force microscopy, fluorescence determination, and dynamic light 134 
scattering. The fluorescence of chimerical proteins was determined in a Cary Eclipse 135 
fluorescence spectrophotometer (Varian Inc, Palo Alto, CA) at 510 nm using an 136 
excitation wavelength of 450 nm. Volume size distribution of nanoparticles was 137 
determined by dynamic light scattering at 633 nm (Zetasizer Nano ZS, Malvern 138 
Instruments Limited, Malvern, UK). Atomic force microscopy (AFM) analyses were 139 
performed with a commercial atomic force microscope (PicoSPM 5100 from Molecular 140 
Imaging Agilent Technologies, Inc., Santa Clara, CA, USA) operating in acoustic mode. 141 
 
 
7 
 
Proteins suspended in 166 mM NaCO3H at pH 7.4 were dropped onto a freshly cleaved 142 
mica surface. The substrate was rinsed gently with miliQ water to eliminate the salts of 143 
the buffer solution and let to air dry before imaged. For the acoustic mode 144 
measurements, a monolithic supersharp silicon SSS-NCH-50 (Nanosensors, Inc.) tip, 145 
with a radius of 2 nm, a nominal spring constant of 10–130 N/m and a resonance 146 
frequency of 204–497 kHz were used. 147 
2.4. Flow cytometry. MDA-MB-231, MCF-7, HEK-293-T and HepG2 cells were 148 
cultured on a 24-well plate at 8·104, 1·105, 8·104 and 1.2·105 cells/well respectively with 149 
their correspondent medium for 24 h until reaching 70 % confluence. Medium was 150 
removed and cells were washed twice with PBS (Sigma-Aldrich Chemie GmbH, 151 
Steinheim, Germany), and then OptiPro medium supplemented with L-glutamine and 152 
peptide at the desired concentration was added and incubated for 24 h at 37ºC and 5% 153 
CO2 in a humidified atmosphere. Cells were detached using 1 mg/mL trypsin for 15 min 154 
followed by the addition of complete medium and centrifuged at 1200 rpm for 15 min. 155 
After supernatant was removed, the cell pellet was resuspended in 300 µl DPBS Ca2+, 156 
Mg2+-free (Invitrogen). Protein internalization was analyzed using a FACS-Canto 157 
system (Becton Dickinson, Franklin Lakes, NJ) using a 15 mW air-cooled argon ion 158 
laser at 488 nm excitation. Experiments were performed in duplicate. 159 
2.5. Protein internalisation monitored by confocal laser scanning microscopy. 160 
MDA-MB-231 cells were plated on a MatTek culture dish (MatTek Corporation, 161 
Ashland, MA) at 200.000 cells/plate for 24 h. Medium was removed and cells were 162 
washed with DPBS, OptiPro medium supplemented with L-glutamine and peptide at 163 
1.5 µM was added and incubated for 24 h at 37ºC and 5 % CO2 in a humidified 164 
atmosphere before confocal analysis. Plasma membranes were labelled with 2.5 165 
μg/mL CellMaskTM Deep Red (Molecular Probes, Eugene, OR) and cell nuclei with 0.2 166 
μg/mL Hoechst 33342 (Molecular Probes) for 10 min. in the dark before confocal 167 
analysis. Cells were washed in PBS and complete medium was added. Analysis was 168 
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performed using a TCS-SP5 confocal laser scanning microscope (Leica Microsystems, 169 
Heidelberg, Germany) using a Plan Apo 63 ×/1.4 (oil HC × PL APO lambda blue) 170 
objective as described elsewhere (Vazquez, Roldan et al., 2010). Images were 171 
processed using Imaris version 6.1.0 software (Bitplane, Zürich, Switzerland).  172 
2.6. Analysis of protein stability and cytoxicity. Stability of A5G27-GFP-H6 and 173 
FNI/II/V-GFP-H6 was analysed in duplicate in human serum (S2257-5ML, Sigma, St 174 
Louis, MO) at 37°C, with agitation and at a final concentration of 0.115 μg/μL and 0.055 175 
μg/μL respectively. Fluorescence was determined as previously described. Cell viability 176 
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 177 
assay using VICTOR3V 1420 (Waltham, USA).  178 
2.7. Determination of CD44 expression. 1.5·106 of each MDA-MB-231, MCF-7, HEK 179 
293 T and HepG2 cells were tripsinised and centrifuged (1,200 rpm, 5 min, 4ºC) and 180 
fixed in 100 µl of 2 % formaldehyde for 10 min at room temperature. The pellet was 181 
washed with PBS-BSA. Cells were then resuspended in 75 µl of blocking solution 182 
(Human Ig 200 µg/mL PBS) for 15 min at room temperature, and aliquoted into 3x25 µl 183 
fractions. 5 µl of APC Mouse IgG2b κ Isotype control (BD Pharmingen, 555745) and 5 184 
µl of APC Mouse Anti-Human CD44 (BD Pharmingen, 559942) were added to two of 185 
these samples respectively. 45 min after incubation at 4ºC out from light, samples were 186 
centrifuged (8,000 rpm, 15 sec, 4ºC) and washed with 1 ml PBS-BSA (0.5 %). Pellet 187 
was resuspended in 500 µl PBS. Samples were analysed in duplicate with a 188 
FacsCalibur cytometer (Becton Dickinson, Franklin Lakes, NJ).     189 
2.9. Peptide internalisation under CD44 deregulation and competition assays. 190 
MDA-MB-231 cells were cultured on a 24 well-plate at 8·104 c/w for 24 h until 70 % 191 
confluence. Medium was removed and cells washed twice with PBS. 250 µl of OptiPro 192 
medium supplemented with L-glutamine with the CD44 expression regulator/competitor 193 
was added. Competitor anti-CD44 and downregulator anti-IL-10 polyclonal antibodies 194 
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(HCAM sc-7946 and IL-10 sc-7888 respectively, Santa Cruz Biotechnology Inc., 195 
Heidelberg, Germanyand) were used at 0.3 µM whereas positive regulatorFGF2 was 196 
added at different ratios (1:1, 1:10, 1:30). After 1 h incubation of regulator/competitor at 197 
37ºC, proteins were added at 0.3 µM. Cells were detached and prepared for cytometry 198 
analysis as described above.  199 
2.10. Statistical analysis. Mean data and other statistics were calculated with 200 
Sigmaplot 10.0.201 
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Table 1. CD44 peptidic ligands used to tag GFP-H6 monomers. 202 
Source protein and 
reference 
CD44 ligand 
protein 
segment 
Length 
(in 
amino 
acids) 
Number of 
positively 
charged residues 
(arg + lys) 
Amino acid 
sequence 
Particle formation and 
size of monomer or 
oligomer  (nm/PDI
a
) 
Construct name. The N-
terminal module corresponds 
to the peptide ligand. 
Fibronectin, 
HBFN‐fragment I, 
(Jalkanen and 
Jalkanen, 1992; 
Yasuda, Poole et al., 
2003) 
1977-1991 15 5 KNNQKSEPLIGRKKT No, 6.3/0.7 FNI-GFP-H6 
Fibronectin, 
HBFN‐fragment V, 
(Jalkanen and 
Jalkanen, 1992; 
Yasuda, Poole et al., 
2003) 
1923-1930 8 2 WQPPRARI No, 5.5/0.8 FNV-GFP-H6 
Fibronectin, HBFN‐I/II/V 
containing fragment, 
(Jalkanen and 
Jalkanen, 1992; 
Yasuda, Poole et al., 
2003)  
1923-1991 69 12 WQPPRARITGYIIKY
EKPGSPPREVVPRP
RPGVTEATITGLEPG
TEYTIYVIALKNNQKS
EPLIGRKKT 
Yes, 13.7/0.4 FNI/II/V-GFP-H6 
Laminin α5 chain, 
peptide A5G27, 
(Hibino, Shibuya et al., 
2004; Hibino, Shibuya 
et al., 2005) 
2975-2987 13 2 RLVSYNGIIFFLK Yes, 13.8/0.4 
b
 A5G27-GFP-H6 
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P7, phage display 
derived peptide, (Park, 
Lee et al., 2012) 
- 12 2 FNLPLPSRPLLR No, 6.5/0.4 P7-GFP-H6 
a The indicated size refers to the peak determined by DLS. PDI is the polydispersity index in the DLS measurements. 203 
b Slight discrepancies between the size of A5G27-GFP-H6 nanoparticles determined here and in a previous report (Unzueta, Cespedes et al., 204 
2012) are due to the different composition of the buffers used in these studies.205 
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3. Results 206 
Five known peptidic ligands of CD44 (FNI, FNV, FNI/II/V, A5G27 and P7, Table 1) 207 
were fused to C-terminal H6-tagged GFP following a previously described approach 208 
(Figure 1 A, (Unzueta, Ferrer-Miralles et al., 2012)), to construct multidomain GFP 209 
protein versions with affinity for CD44+ cells. All these constructs were efficiently 210 
produced in bacteria, resulting in full length polypeptides with expected mass and 211 
predicted N-terminal amino acid sequence (see Supplementary Figure 1). Before 212 
testing for biological properties, the potential self-assembling of protein monomers into 213 
higher order entities was explored. According to a previously proposed model 214 
(Unzueta, Ferrer-Miralles et al., 2012), the highly cationic peptide FNI/II/V was 215 
expected to promote the formation of ordered oligomers within the nanoscale. In this 216 
regard, FNI/II/V-GFP-H6 in solution peaked at around 14 nm by DLS (Figure 1 B, Table 217 
1), indicative of nanoparticle formation. The unassembled GFP-H6 protein showed a 218 
size of 6 nm (Vazquez, Roldan et al., 2010), and FNI, FNV and P7-empowered GFP 219 
proteins peaked at the same size, indicating that they remained unassembled like the 220 
parental GFP-H6 (Figure 1 B, Table 1). Unexpectedly, A5G27, even being poorly 221 
cationic (Table 1), also promoted the formation of supramolecular entities of 14 nm 222 
(Figure 1 B, Table 1).  223 
When the nanoparticulate architecture of FNI/II/V-GFP-H6 and A5G27-GFP-H6 was 224 
assessed by AFM, these proteins clearly organized as regular nanoparticles with a size 225 
fully compatible with DLS determinations (Figure 1C-G). Some A5G27-GFP-H6 226 
particles appeared as rings or pseudorings with a centred cavity (Figure 1E), and such 227 
a ring-based architecture was generic in FNI/II/V-GFP-H6 samples, in which some of 228 
the nanoparticles showed a pentameric organization (Figure 1F). In this regard, 229 
molecular modelling of R9-GFP-H6 nanoparticles indicated a pentameric organization 230 
of the constructs (Unzueta, Ferrer-Miralles et al., 2012; Vazquez, Cubarsi et al., 2010; 231 
Vazquez, Roldan et al., 2010) and size-exclusion chromatography of several GFP and 232 
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iRFP-based nanoparticles also showed pentamers as a basic module resulting from 233 
self-assembling in protein particles empowered by cationic stretches plus H6 234 
(Cespedes, Unzueta et al., 2014). 235 
To evaluate the biological properties of the fusion proteins, namely cell penetration and 236 
eventual intracellular trafficking, we first checked the specific fluorescence of all fusion 237 
proteins, as fluorescence emission is a convenient reporter to monitor cell binding and 238 
internalization. As observed (Figure 2 A), fluorescence emission of the enhanced GFP 239 
was not straightforward affected by protein fusion but it was reduced up to around 30-240 
40 % of the parental protein in A5G27-GFP-H6 and FNI/II/V-GFP-H6. The coincidence 241 
between fluorescence dropping and nanoparticle formation might be indicative of a 242 
slight quenching effect associated to oligomer formation. Irrespectively of the precise 243 
cause, fluorescence levels were well acceptable and sufficient for further analyses. An 244 
important fraction of CD44+ MDA-MB-231 cells were fluorescent when exposed to 245 
A5G27-GFP-H6 and FNI/II/V-GFP-H6 (around 80 % vs 40 % or less in the case of 246 
other fusions, Figure 2B), and a higher global fluorescence emission was observed in 247 
cell cultures exposed to these proteins when compared with alternative GFP versions 248 
(between 1000 and 2000 vs up to 600, Figure 2C). In both experimental approaches 249 
and as it was expected, GFP-H6 only rendered background values. In agreement with 250 
quantitative data, confocal analyses of protein-exposed MDA-MB-231 cell cultures 251 
confirmed the high penetrability of A5G27-GFP-H6 and FNI/II/V-GFP-H6 vs alternative 252 
GFP versions, mostly showing a background uptake (Figure 2D). Note that as indicated 253 
above, the lower specific fluorescence of these two constructs resulted in an 254 
underestimation of the internalized material when compared to alternative ligands. 255 
Considering the values presented in the Figure 2B, A5G27-GFP-H6 and FNI/II/V-GFP-256 
H6 internalized 20 times more efficiently than the alternative fusion proteins. Again, the 257 
parental, H6-tagged GFP was seen as totally excluded from cultured cells. The 258 
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incorporation of the internalized recombinant proteins into membranous vesicles was 259 
clearly observed and it was indicative of endosomal uptake (Figure 2D). 260 
Internalization of A5G27-GFP-H6 and FNI/II/V-GFP-H6 occurred very fast, and the 261 
fraction of target cells and the amount of intracellular protein reached a plateau at 262 
about 10 h (Figure 3A). Interestingly, the penetration of these nanoparticles did take 263 
place without compromising cell viability (Figure 3B), again in agreement with the 264 
occurrence of an endosomal route and supporting the full biocompatibility nature of 265 
protein-only nanoparticles. In this context, both A5G27-GFP-H6 and FNI/II/V-GFP-H6 266 
were fully stable when incubated in human serum (Figure 3C), a fact that confirmed the 267 
structural robustness of the particles and prompted us to envisage a potential for 268 
proper biodistribution of these materials in targeted drug delivery or diagnostic 269 
applications. 270 
To assess the receptor-driven specificity of the cell penetration, the uptake of protein 271 
nanoparticles was explored in several cell lines, expressing and not expressing CD44, 272 
namely MDA-MB-231, MCF-7, Hep G2 and HEK-293T. A differential cell penetrability 273 
of A5G27-GFP-H6 and FNI/II/V-GFP-H6 was observed (Figure 4A), coincident with the 274 
amount of cellular CD44 in the target cells (Figure 4B). This fact strongly supported the 275 
CD44-dependence of cell binding. In this context, a commercial polyclonal anti-CD44 276 
serum inhibited the entrance of both type of nanoparticles (Figure 5). Finally, we 277 
wanted to determine if the externally mediated up- or down-regulation of CD44 278 
expression could have enhancing or inhibiting effects on the penetration of 279 
nanoparticles, as expected. The fibroblast growth factor 2 (FGF-2), a positive regulator 280 
of CD44 (Grimme, Termeer et al., 1999; Jones, Tussey et al., 2000), stimulated the cell 281 
penetrability of A5G27-GFP-H6 (Figure 6A), while the blocking of interleukin-10 (IL-10; 282 
also a positive regulator of CD44, (Gee, Kryworuchko et al., 2004)) by a specific 283 
antibody reduced the uptake of the nanoparticle (Figure 6B). By the combination of 284 
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these data, the CD44-targeting of the protein constructs developed here was fully 285 
demonstrated.  286 
287 
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4. Discussion 288 
Developing tools for targeted drug delivery is a priority in targeted medicines of cancer 289 
and other prevalent diseases (Ruoslahti, Bhatia et al., 2010; Vicent and Duncan, 2006). 290 
While of the number of  cell surface proteins identified as valuable markers are rapidly 291 
expanding (Gonzalez-Angulo, Hennessy et al., 2010; Klonisch, Wiechec et al., 2008; 292 
Mocellin, Lise et al., 2005; Nguyen and Massague, 2007; Ruoslahti, Bhatia et al., 2010; 293 
Sawyers, 2008; Tjalsma, 2010), efficient and secure vehicles are still missing. While 294 
consensus exists in that nanoscale containers are ideal for competent systemic 295 
transport, diffusion in the tissue and cell penetrability (Mastrobattista, van der Aa et al., 296 
2006), a fully biocompatible material remains to be developed. In this regard, the 297 
number of nanomedicines so far approved by the medicament agencies is still limited 298 
(Duncan and Gaspar, 2011).  299 
A promising route to the generation of efficient vehicles for drug delivery is 300 
conventional genetic engineering, since proteins are fully biocompatible and functional 301 
macromolecules. The ability to recruit diverse peptides from distinct origins and with 302 
different complementing activities in a single chain protein offers promise to generate 303 
constructs showing the biological properties exhibited by viruses during infection. 304 
These include stable systemic circulation, receptor targeting, internalization, 305 
intracellular trafficking and accumulation into the appropriate compartment (Aris and 306 
Villaverde, 2004; Ferrer-Miralles, Vazquez et al., 2008; Vazquez, Ferrer-Miralles et al., 307 
2009; Vazquez, Ferrer-Miralles et al., 2008). Despite this potential, the exploration of 308 
how protein-protein contacts could be engineered to construct protein-only 309 
nanoparticles has been in general neglected. The adaptation of virus-like particles 310 
(VLP) (Ma, Nolte et al., 2012), bacterial micro compartments (BMC) (Corchero and 311 
Cedano, 2011), eukaryotic vaults (Rome and Kickhoefer, 2012) or other natural protein 312 
constructs (Rodriguez-Carmona and Villaverde, 2010) poses severe limitations, as  313 
conferring new tropisms might in general alters the stability of the particle. However, 314 
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recent lessons about how protein-protein interactions can be engineered for self-315 
assembling in fully de novo designed protein constructs {Neus Ferrer-Miralles, 2013 316 
1106 /id;Unzueta, 2014 1308 /id;Villaverde, 2012 7494 /id} should permit to approach 317 
an ‘artificial virus’ strategy for the design of novel nanomedicines (Mastrobattista, van 318 
der Aa et al., 2006). Importantly, the recent advances in systems and synthetic 319 
biotechnology and industrial microbiology (Lee, Mattanovich et al., 2012) allow the 320 
large scale biosynthesis of natural proteins and protein constructs, being biological 321 
biofabrication highly versatile (Vazquez and Villaverde, 2013) and progressively more 322 
competitive with regard to conventional chemical synthesis (Chen, 2012). 323 
We have here constructed a set of five modular polypeptides intended to target CD44+ 324 
cells (Table 1). Among them, two constructs (empowered by peptides A5G27 and 325 
FNI/II/V respectively), self-organize as stable nanoparticles (Figure 1 and 3C) that 326 
efficiently bind and internalize CD44+ target cells (Figure 4), accumulating in the 327 
perinuclear and nuclear regions (Figure 2). Since the five peptides used here are very 328 
well known ligands of CD44 (Table 1),  the coincidence between nanoparticle formation 329 
and internalization strongly suggests that the presentation of a given protein in form of 330 
nanoparticle (versus the plain monomeric form) stimulates cell penetration. This is 331 
probably because of the multiple ligand display and multivalent cross-linking at the cell 332 
surface, favoring membrane wrapping (Jiang, Kim et al., 2008), and in the line of 333 
nanoparticle size being a main determinant of interactions with cells (Jiang, Kim et al., 334 
2008). Also, this is in agreement with the high penetrability found in natural oligomers 335 
when displaying cell-binding peptides (Aris and Villaverde, 2003; Villaverde, Feliu et al., 336 
1998). 337 
While other engineering principles have been recently proposed to control protein self-338 
assembling (Bai, Luo et al., 2013) (King, Sheffler et al., 2012), the approach based on 339 
the end terminal fusion of a cationic peptide and a polyhistidine is not restricted to a 340 
unique core protein. This versatility would be convenient to avoid immunogenicity of the 341 
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constructs by selecting homologous proteins in next generation-constructions. By using 342 
the end-terminal peptide-pair strategy, the formation of nanoparticles with pentameric, 343 
toroid-like organization had been previously predicted (Unzueta, Ferrer-Miralles et al., 344 
2012; Vazquez, Roldan et al., 2010) and demonstrated by FESEM for a certain 345 
category of proteins (those empowered by the cationic peptide T22) (Cespedes, 346 
Unzueta et al., 2014). The highly resolutive AFM has confirmed this particular 347 
architecture also for A5G27-GFP-H6 and FNI/II/V- GFP-H6 (Figure 1E,F), indicative 348 
that the ring shaped distribution of the building blocks is not restricted to an unique type 349 
of end-terminal tags. Being highly cationic (Table 1), the oligomerization of FNI/II/V-350 
GFP-H6 was fully anticipated at the upstream stage, while the formation of A5G27-351 
GFP-H6-based nanoparticles (being A5G27 poorly cationic) was unexpected. Acting 352 
the amino terminal stretch both as architectonic tag and cell ligand, the promotion of 353 
protein self-assembling by a non-cationic peptide expands, in any case, the spectrum 354 
of potential ligands usable for the formation of cell-targeted nanoparticles, so far 355 
restricted to cationic protein regions.  356 
Laminin and fibronectin ligands bind CD44 through chondroitin and heparin-like GAG 357 
side chains, especially by the heparin-sulphate found in CD44v3 and CD44v6 isoforms. 358 
On the other hand, the alternative CD44 ligand HA binds to a binding site termed the 359 
“link module” which is a domain expressed in all CD44 isoforms and it is located on 360 
CD44 most exposed region (far from V3 and v6 variant regions) (Peach, Hollenbaugh 361 
et al., 1993). Therefore, although HA could not be used as a competitor to probe the 362 
CD44 targeting of the protein constructs developed here, the specificity in binding and 363 
internalization was successfully demonstrated by the coincidence between CD44 levels 364 
and penetrability (Figure 4), by inhibition mediated by a polyclonal anti-CD44 serum 365 
(Figure 5), and though the external alternate regulation of CD44 levels and the 366 
consequent variation in the efficiency of nanoparticle uptake (Figure 6). 367 
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In summary, we have developed smart and stable protein-only nanoparticles (A5G27-368 
GFP-H6 and FNI/II/V-GFP-H6) as plastic agents that bind specifically CD44+ cells and 369 
that are efficiently internalized by receptor-mediated endocytosis in absence of cell 370 
toxicity. Interestingly, the vehicle itself is composed by fully functional (fluorescent, in 371 
our model system) proteins, what opens a plethora of possibilities regarding the 372 
targeted delivery of therapeutic polypeptides in form of nanoparticles. The 373 
nanostructure gained by these proteins would desirably allow them escaping from renal 374 
clearance, as the final size of the constructs is largely over the 6-7 nm cut-off. In 375 
addition, protein nanoparticles could be loaded with chemically coupled conventional 376 
drugs, as the principle of protein-drug coupling has been largely proved in already 377 
licensed drugs (Elzoghby, Samy et al., 2012). Altogether, and according to recent data 378 
proving the high stability in vivo (Cespedes, Unzueta et al., 2014) and efficient 379 
biodistribution of similar protein-only modular constructs (Unzueta, Cespedes et al., 380 
2012), the tools generated here are promising platforms as vehicles for drugs and 381 
imaging agents, in the context of emerging nanomedines for breast cancer and other 382 
metastatic CD44-linked tumours based on biocompatible and versatile protein 383 
materials. 384 
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Figure legends: 553 
 554 
Figure 1. Construction and nanoscale characterization of CD44-targeted protein 555 
nanoparticles. A) Schematic representation of the gene fusion scheme used in this 556 
study. L represents a CD44 ligand that in some cases also has an architectonic role. B) 557 
Size distribution of the protein constructs determined by DLS. Numerical values are 558 
given in Table 1. C) AFM images of randomly selected A5G27-GFP-H6 nanoparticles. 559 
D) Topography cross- section of one randomly selected isolated A5G27-GFP-H6 560 
nanoparticle. E) Topography cross- section of two ring shaped A5G27-GFP-H6 nano 561 
particles. F) AFM images of randomly selected FNI/II/V-GFP-H6 nanoparticles, 562 
showing the topography cross- section of one isolated particle. G) Images of a 563 
pentameric particle are shown. Measurements have been done with a tip radius of 2 564 
nm and thus the width (but not the high) of the particles is inherently overestimated. An 565 
AFM image is a convolution of the imaging tip shape/size with the actual shape of the 566 
imaged object (Allen, Hud et al., 1992). Thus, one will observe broadening of the 567 
sample features. 568 
  569 
Figure 2. Internalization of CD44-targeted protein nanoparticles. A) Specific 570 
fluorescence of the different protein constructs in comparison to that of the parental 571 
GFP-H6 (in green). The specific green fluorescence of the parental protein is 1,021 572 
fluorescence units (FU)/ug. B) Percentage of MDA-MB-231 cells that are fluorescent 573 
after 24 h exposure to the multidomain proteins. C) Green fluorescence emitted by 574 
MDA-MB-231 cells after 24 h exposure to multidomain proteins. D) Confocal sections 575 
or projections of MDA-MB-231 cells upon 24 h of exposure to multidomain proteins. 576 
Bars indicate 20 µm. E) Details of target cells during the uptake of fusion proteins, 577 
indicating the exogenous material (in green) included in endosomes (red signal). 578 
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Merging into yellow is evident in some cases. A 3D projection is included in the case of 579 
FNI/II/V-GFP-H6. 580 
 581 
Figure 3. Kinetics of cellular internalization of CD44-targeted protein nanoparticles, 582 
cytotoxicity and protein serum stability. A) Time course cell penetration of protein-only 583 
nanoparticles at 1.5 µM. Percentatge of protein-internalised cells (left) and cell EGFP 584 
fluorescence intensity (right). B) MTT viability analysis of MDA-MB-231cells upon 585 
exposure to different doses of protein nanoparticles for 24,48 and 72h.. C) Stability of 586 
protein nanoparticles in human. Fluorescence emission of serum samples with 587 
nanoparticle incubation at different time point up to 24 hours. Soluble 24h corresponds 588 
to fluorescence of soluble fraction from 24 hours sample after centrifugation to discard 589 
nanoparticle aggregation/precipitation 590 
Figure 4: Specific internalization of CD44-targeted protein nanoparticles in CD44-591 
expressing and not expressing cells. A) Percentage of cells uptaking A5-GFP-H6 (left) 592 
and FNI/II/V-GFP-H6 (right) in CD44-overexpressing MDA-MB-231 and MCF-7 lines 593 
and in Hep G2 and HEK 293 T lines. B) Histograms of CD44-expressing cell population 594 
from CD44+ cell lines MDA-MB-231 and MCF-7 and CD44- cell lines HepG2 and HEK-595 
293-T. APC-anti-CD44 marked cells (red) are compared with isotopic control cells 596 
(black). FL4-H axis corresponds to APC intensity. The percentage of CD44+ cells is 597 
indicated. 598 
Figure 5: Anti-CD44 mediated inhibition of nanoparticle internalization. Decrease on 599 
the intensity of intracellular fluorescence mediated by 0.3 µM of either A5G27-GFP-H6 600 
or FNI/II/V-GFP-H6 (control: back bar) when adding 0.3 µM polyclonal anti-CD44 (ratio 601 
1:1). A control of GFP-H6 incubation with anti-CD44 is presented. 602 
 603 
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Figure 6: Modulation of nanoparticle internalization through CD44 regulation. A) 604 
Enhanced cell entry (left) and fluorescence intensity (right) of A5G27-GFP-H6 605 
incubation at 0.3 µM after 1 h of cell exposure to increasing amounts of FGF2 (ratios 606 
1:1, 1:10 and 1:30) due to CD44 receptor overexpression mediated by FGF2-H6. B) 607 
Reduced cell entry (left) and fluorescence intensity (right) of A5G27-GFP-H6 incubation 608 
at 0.3 µM after 1 h of cell exposure to anti-IL10 antibody due to an inhibition of IL-10-609 
induced CD44 expression mediated by polyclonal anti-IL10.  610 
